BioMaxima S.A.

Warsaw Stock Exchange BMX.WA

BioMaxima S.A. Cash and Short-Term Investments for the year ending December 31, 2023: USD 381.15 K

BioMaxima S.A. Cash and Short-Term Investments is USD 381.15 K for the year ending December 31, 2023, a -87.07% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

BioMaxima S.A. Cash and Short-Term Investments for the year ending December 31, 2022 was USD 2.95 M, a 3,613.51% change year over year.
BioMaxima S.A. Cash and Short-Term Investments for the year ending December 31, 2021 was USD 79.41 K, a -93.24% change year over year.
BioMaxima S.A. Cash and Short-Term Investments for the year ending December 31, 2020 was USD 1.17 M, a 782.23% change year over year.
BioMaxima S.A. Cash and Short-Term Investments for the year ending December 31, 2019 was USD 133.11 K, a -51.81% change year over year.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

Warsaw Stock Exchange: BMX.WA

BioMaxima S.A.

CEO	Mr. Lukasz Urban
IPO Date	July 21, 2010
Location	Poland
Headquarters	ul. VetterOw 5
Employees	115
Sector	Consumers Staples
Industries Personal Care Biotechnology Cleaning Supplies Fertilizers Medical Instruments Petrochemicals Pharmaceuticals Plastics

Description

BioMaxima S.A. manufactures and distributes reagents for in vitro diagnostics in Poland. Its primary products include diagnostic reagents and analyzers for clinical chemistry; rapid tests and readers for detecting infectious diseases, cancer markers, cardiac markers, and drugs of abuse; urine analysis systems; hematology analyzers and reagents; ionselective analyzers and reagents; reagents and immunological analyzers of cardiac markers; glucometers for professional use; and analyzers for gasometric tests and critical blood parameters tests. The company also provides surfaces and air controls; antibiotics discs and MIC strips; and chromogenic, dehydrated, and prepared culture media; and additives and supplements for media. It supplies its products to approximately 2,000 laboratories in Poland, as well as exports in the international markets. BioMaxima S.A. was founded in 2002 and is based in Lublin, Poland.

Key trends

Past 5 years